We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide delivers strong revenue growth and marked improvement in profitability
12 Mar 2026 - Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 […]
Read morePolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
19 Jan 2026 - Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its […]
Read morePolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
12 Aug 2025 - Baar, 12 August 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2025, […]
Read morePolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
11 Mar 2025 - Baar, 11 March 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2024 […]
Read moreSolid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028
13 Aug 2024 - Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2024, […]
Read morePolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
12 Mar 2024 - Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read moreTransformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
15 Aug 2023 - Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported results […]
Read morePolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read morePolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
3 Apr 2023 - Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read more